

CLAIMS

1. An isolated antibody that binds to sialyl(α 2,6)N-acetylgalactosamine (STn), wherein the antibody comprises a heavy chain variable domain (VH) comprising an amino acid sequence selected from SEQ ID NOs: 240, 237-239, and 241, and a light chain variable domain (VL) comprising an amino acid sequence selected from SEQ ID NOs: 235 and 236.
2. The isolated antibody of claim 1, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 240 and a VL comprising the amino acid sequence of SEQ ID NO: 235.
3. The isolated antibody of claim 1 or claim 2, wherein the antibody comprises a human IgG1, IgG2, IgG3, or IgG4 constant region.
4. The isolated antibody of claim 1 or claim 2, wherein the antibody comprises a human IgG1 constant region.
5. The isolated antibody of any one of claims 1-4, wherein the antibody binds to cell-associated STn with a half maximal effective concentration (EC₅₀) of from 0.01 nM to 30 nM.
6. A pharmaceutical composition comprising the antibody of any one of claims 1-5 and at least one pharmaceutically acceptable excipient.
7. An isolated nucleic acid that encodes an antibody of any one of claims 1-5.
8. The isolated nucleic acid of claim 7, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 240 and a VL comprising the amino acid sequence of SEQ ID NO: 235.
9. An isolated host cell that comprises the nucleic acid of claim 7 or claim 8.
10. An isolated host cell that expresses the antibody of any one of claims 1-5.
11. A method of producing an antibody that binds to sialyl(α 2,6)N-acetylgalactosamine (STn), comprising culturing the host cell of claim 9 or claim 10 under conditions suitable for expressing the antibody.
12. The method of claim 11, further comprising isolating the antibody.
13. Use of the antibody of claim 4 in the manufacture of a medicament for treating cancer in a subject, wherein the cancer comprises STn-expressing cancer cells.
14. The use of claim 13, wherein the antibody comprises a VH comprising the

amino acid sequence of SEQ ID NO: 240 and a VL comprising the amino acid sequence of SEQ ID NO: 235.

15. The use of claim 13 or claim 14, wherein the cancer is selected from breast cancer, colon cancer, pancreatic cancer, lung cancer, cervical cancer, ovarian cancer, stomach cancer, prostate cancer, and liver cancer.

16. The antibody of any one of claims 1-5 for use in a method of selecting a subject with cancer for treatment with a therapeutic anti-STn antibody, wherein the method comprises contacting a sample from the subject with the antibody; and detecting binding of the antibody to STn-expressing cancer cells.

~~17. The antibody for use of claim 16, further comprising administering the therapeutic anti-STn antibody to the subject.~~

~~18.~~17. The antibody for use of claim 16 ~~or claim 17~~, wherein the sample is a cell, a tissue, a tissue section, a body fluid, serum, or a combination thereof.

~~19.~~18. A kit for screening a biological sample for the presence of STn-expressing cancer cells, comprising an antibody of any one of claims 1-5.

~~20.~~19. An antibody-drug conjugate comprising an antibody conjugated to a therapeutic agent, wherein the antibody is an antibody of any one of claims 1-5.

~~21.~~20. The antibody-drug conjugate of claim ~~20~~19, wherein said therapeutic agent is a cytotoxic agent.

~~22.~~21. The antibody-drug conjugate of claim ~~21~~20, wherein said cytotoxic agent is monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF).

~~23.~~22. The antibody-drug conjugate of claim ~~22~~21, wherein the cytotoxic agent is MMAE.

~~24.~~23. The antibody-drug conjugate of any one of claims ~~20~~19-23~~22~~, wherein the VH comprises the amino acid sequence of SEQ ID NO: 240 and the VL comprises the amino acid sequence of SEQ ID NO: 235.

~~25.~~24. A pharmaceutical composition comprising the antibody-drug conjugate of any one of claims ~~20~~19-24~~23~~ and at least one pharmaceutically acceptable excipient.

~~26.~~25. Use of the antibody-drug conjugate of any one of claims ~~20~~19-24~~23~~ or the pharmaceutical composition of claim ~~25~~24 in the manufacture of a medicament for treating cancer in a subject, wherein the cancer comprises STn-expressing cancer cells.

~~27.26.~~ The use of claim ~~2625~~, wherein the cytotoxic agent is MMAE.

~~28.27.~~ The use of claim ~~2625~~ or claim ~~2726~~, wherein the VH comprises the amino acid sequence of SEQ ID NO: 240 and the VL comprises the amino acid sequence of SEQ ID NO: 235.

~~29.28.~~ The use of any one of claims ~~2625-2827~~, wherein the cancer is selected from breast cancer, colon cancer, pancreatic cancer, lung cancer, cervical cancer, ovarian cancer, stomach cancer, prostate cancer, liver cancer, gastric cancer, endometrial cancer, esophageal cancer, and colorectal cancer.

~~30.29.~~ An in vitro method of killing a STn-expressing cell, comprising contacting the cell with an antibody-drug conjugate of any one of claims ~~2019-2423~~.

~~31.30.~~ A method of making an antibody-drug conjugate, comprising contacting an antibody that binds to sialyl(α 2,6)N-acetylgalactosamine (STn) with maleimidocaproyl-valine-citruline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E (MC- γ c-PAB-MMAE), wherein the antibody is an antibody of any one of claims 1-5.

~~32.31.~~ The method of claim ~~3130~~, wherein the VH comprises the amino acid sequence of SEQ ID NO: 240 and the VL comprises the amino acid sequence of SEQ ID NO: 235.